

To: Simpson, Edward J SCC-BC-AM
<Edward.Simpson@shell.com>; Moorad, Judith C SHLOIL-
OME/2 <judith.moorad@shell.com>; Colletti, Sarah J SCC-
CSEA <sarah.colletti@shell.com>; Schmit, Allen F SOPUS-
OP-COR-H <allen.schmit@shell.com>
From: Clegg, Patsy M SCC-CHSE-PC
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>
Cc: Cagen, Stuart Z SCC-CF-SS <stuart.cagen@shell.com>;
Semmler, Klaus K DSC-CHSE-KS
<klaus.semmler@shell.com>
Bcc:
Received Date: 2005-09-09 19:57:45 GMT
Subject: Benzene MSDS released with significant new tox
information

Ed, Judith, Sarah and Al;

The Shell Chemicals benzene MSDS will be released as a new version next week with language added in Chapter 11, Toxicology Data, describing myelodysplastic syndrome (MDS) as a potential adverse effect at high exposures. This is new information coming out of the Shanghai Health Study. Both Shell and ExxonMobil have filed TSCA 8(e) reports on this.

Below is the added MSDS language:

Myelodysplastic syndrome (MDS) was observed in individuals exposed to very high levels (50 ppm to 300 ppm range) of benzene over a long period of time in the workplace. The relevance of these results to lower levels of exposure is not known.

Ed, I would recommend that we do a special customer communication regarding this change.

Judith, I would recommend that we do a special employee notification.

Sarah, would you please help draft the customer and employee communications?

Al, I would recommend that OP consider adding this statement to their benzene MSDS.

Regards,
Patsy

Patsy Clegg
Product Steward, HSSE
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 **Fax:** 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Business Success through HSSE Excellence
